Bayer Grant Promotes Groundbreaking Hemophilia Research and Education; Bayer Hemophilia Awards Program Continues to Be a Critical Source of Funding for Hemophilia Research and Education.VANCOUVER, British Columbia British Columbia, province (2001 pop. 3,907,738), 366,255 sq mi (948,600 sq km), including 6,976 sq mi (18,068 sq km) of water surface, W Canada. Geography -- Bayer HealthCare Pharmaceuticals (Bayer) announced today it is awarding $2.75 million in grant money through the Bayer Hemophilia hemophilia (hē'məfĭl`ēə,–fēl`yə), genetic disease in which the clotting ability of the blood is impaired and excessive bleeding results. Awards Program (BHAP). The funding will support 25 cutting-edge research and education projects in hemophilia and related bleeding disorders Bleeding disorder Problems in the clotting mechanism of the blood. Mentioned in: Lithotripsy bleeding disorder Coagulopathy, see there . Bayer honored the 26 recipients during a special awards dinner and ceremony in conjunction with the 2006 WFH WFH World Federation of Hemophilia (Fédération Mondiale de l'Hémophilie) WFH Working From Home WFH Willem Frederik Hermans (Dutch writer) WFH Work for Hire WFH World Federation of Healing World Congress in Vancouver. The awardees represent 13 countries, and many of the research programs will support efforts to improve the lives of people around the world who are living with hemophilia. One recipient of the 2006 Special Projects Award, Dr. Julie Curtin, Children's Hospital A children's hospital is a hospital which offers its services exclusively to children. The number of children's hospitals proliferated in the 20th century, as pediatric medical and surgical specialties separated from internal medicine and adult surgical specialties. of Westmead, Australia, plans to study the impact of exercise in children with hemophilia. "So many parents are worried that exercise can cause more harm than good in children with hemophilia," said Curtin. "Thanks to this grant from Bayer, I will have the opportunity to study the health and quality of life implications of exercise, which could have a dramatic impact on the lives of children around the world." BHAP supports projects in four categories: Early Career Investigators, Clinical Scholarships, Special Projects, and Caregivers Education. "We need programs like BHAP because of a shortage of important funding for hemophilia research. Bayer's awards help encourage young, bright researchers, clinicians, and caregivers to focus their careers on hemophilia," said Dr. David Lillicrap, M.D., Queen's University Queen's University, at Kingston, Ont., Canada; nondenominational; coeducational; founded 1841 as Queen's College. It achieved university status in 1912. It has faculties of arts and sciences, education, law, medicine, and applied science, as well as schools of , Ontario, Canada, and chairman of the review committee that selected the recipients. "This year's awardees continue to represent the best and the brightest in the hemophilia field." Since the program's inception in 2002, nearly 100 hemophilia professionals have received grants totaling $11 million. The professional projects supported by BHAP have resulted in 29 scientific publications, nine full papers and 20 abstracts, many of which have been featured in such publications as the Journal of Thrombosis thrombosis (thrŏmbō`sĭs), obstruction of an artery or vein by a blood clot (thrombus). Arterial thrombosis is generally more serious because the supply of oxygen and nutrition to an area of the body is halted. and Haemostasis hemostasis, haemostasis the stoppage of bleeding or cessation of the circulation of the blood; stagnation of the blood in a part of the body. Also hemostasia, haemostasia. See also: Blood and Blood Vessels Noun 1. and Haemophilia and in abstracts at the American Society for Hematology. The 2006 recipients, their institutions, and countries are listed below by category:
Early Career Investigator Award Recipients:
Dr. Junmei Chen Puget Sound Blood Center Seattle, Wash.,
USA
Dr. Bradley Aouizerat University of California- San Francisco,
San Francisco Calif., USA
Dr. Jordan Shavit University of Michigan Ann Arbor,
Mich., USA
Mr. Stefan Heinz J.W. Goethe University Frankfurt,
Germany
Dr. Stefano Duga Dept. of Biology and Genetics Milan, Italy
for Medical Sciences
Dr. Vikram Mathews Christian Medical College Vellore, India
Clinical Scholarship Award Recipients:
Dr. Tina Dutt Royal Liverpool & Broadgreen Liverpool, UK
Univ. Hospitals
Dr. Antioco Meloni Bonomi HTC, University of Milan, Italy
Milan
Dr. Joannis Panotopoulos Medical University of Vienna Vienna, Austria
Dr. Yi Fang Ruijin Hospital Shanghai Shanghai, PR
Institute of Hematology China
Dr. Hsuan-Yu Lin Changhua Christian Hospital Changhua,
Taiwan
Special Projects Award Recipients:
Dr. Nigel Key University of North Chapel Hill,
Carolina N.C.,USA
Dr. Dougald Monroe University of North Chapel Hill,
Carolina N.C.,USA
Dr. Peter Lenting University Medical Utrecht,
Center Utrecht Netherlands
Prof. Johannes Oldenburg University Clinic, Bonn, Germany
University of Bonn
Dr. Massimo Morfini Azienda Ospedaliero - Firenze, Italy
Universitaria Careggi
Dr. Julie Curtin Children's Hospital Westmead,
Australia
Dr. Midori Shima Nara Medical University Nara, Japan
Caregiver Award Recipients:
Diane Bissonnette Children's Hospital of Ottawa, Canada
Eastern Ontario
Mercy Devadarisini Christian Medical College Vellore, India
Kumar Ajoy Hemophilia Society - Durgapur West Bengal,
Chapter India
Luz Garcia Hospital del Nino Panama, Rep. of
Panama
Kumar Mitra & Kashinath Haemophilia Society - West Bengal,
Saha Calcutta Chapter India
Thomas Samuel Christian Medical College Vellore, India
Gopal Singh Christian Medical College Vellore, India
BHAP remains one of the largest programs of its kind. "Bayer fully intends to stay committed to this program. We passionately believe that many projects funded through this program will help shape the future of hemophilia care," said Michael Fournel, Senior Vice President, Research & Development, Bayer HealthCare Pharmaceuticals, Hematology/Cardiology. "These individuals are constantly exploring new frontiers New Frontier President John F. Kennedy’s legislative program, encompassing such areas as civil rights, the economy, and foreign relations. [Am. Hist.: WB, K:212] See : Aid, Governmental in hemophilia research and education, and this program is just one of the ways Bayer helps support them." About the Bayer Hemophilia Awards Program Bayer believes the Hemophilia Awards Program can improve the lives of patients with hemophilia by supporting research and education worldwide. Parties who wish to apply for the 2007 Bayer Hemophilia Awards should submit a letter of intent by November 30, 2006 to be considered. A 13-member Grant Review and Award Committee, representing clinicians and researchers from around the world, selects the group of recipients each year. For complete information on the Bayer Hemophilia Awards Program, award categories, and submission process, visit the Web site at www.bayer-hemophilia-awards.com. About Hemophilia Approximately 400,000 people around the world have hemophilia. Hemophilia is an inherited bleeding disorder characterized by prolonged pro·long tr.v. pro·longed, pro·long·ing, pro·longs 1. To lengthen in duration; protract. 2. To lengthen in extent. or spontaneous bleeding, especially into the muscles, joints, or internal organs. The disease is caused by deficient or defective blood coagulation Noun 1. blood coagulation - a process in which liquid blood is changed into a semisolid mass (a blood clot) blood clotting clotting, coagulation, curdling - the process of forming semisolid lumps in a liquid proteins, known as factor VIII factor VIII n. A factor in the clotting of blood, a deficiency of which is associated with hemophilia A. Also called antihemophilic factor, antihemophilic globulin, antihemophilic globulin A, or IX. The most common form of the disease is hemophilia A hemophilia A n. Hemophilia due to deficiency of factor VIII, characterized by prolonged clotting time, decreased formation of thromboplastin, and diminished conversion of prothrombin. , or classic hemophilia classic hemophilia see hemophilia A. , in which the clotting factor clot·ting factor n. Any of various plasma components involved in the clotting of blood, including fibrinogen, prothrombin, thromboplastin, and calcium ion. Also called coagulation factor. VIII is either deficient or defective. Hemophilia B hemophilia B n. A clotting disorder of blood resembling hemophilia A, caused by hereditary deficiency of factor IX. Also called Christmas disease. is characterized by deficient or defective factor IX. About Bayer HealthCare AG Bayer HealthCare, a subsidiary of Bayer AG Bayer AG German chemical and pharmaceutical company. Founded in 1863 by Friedrich Bayer (1825–1880), it now operates plants in more than 30 countries. Bayer has originated scores of pharmaceuticals, chemicals, and synthetic materials; it was the first developer and , is one of the world's leading, innovative companies in the healthcare and medical products industry, and is based in Leverkusen, Germany. Bayer HealthCare generated sales amounting to approximately 9.4 billion euros and employed 33.800 people worldwide in 2005. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals divisions. The new Pharmaceuticals division was established on January 1, 2006, and comprises the former Biological Products and Pharmaceutical divisions. Pharmaceuticals now has three business units: Hematology/Cardiology, Oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors. on·col·o·gy n. , and Primary Care. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing, and treating diseases. Information about Bayer HealthCare can be found at www.bayerhealthcare.com. Forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties, and other factors could lead to material differences between the actual future results, financial situation, development, or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange Frankfurt Stock Exchange The largest of Germany's eight securities exchanges, operated by Deutsche Borse AS. and the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion